+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

E

Actively Recruiting

Healthy Volunteer

This research aims to compare the effects of submucosal dexamethasone and oral trypsin-chymotrypsin on reducing common postoperative problems like pain, swelling, and difficulty opening the mouth after surgical removal of impacted lower third molars. These issues arise mainly from local inflammation after surgery. The study evaluates how these treatments work to control inflammation and improve recovery. Participants will receive one of two treatments a local injection of 8 mg dexamethasone given under the mucosa near the surgery site before the incision, or oral trypsin-chymotrypsin tablets taken starting 30 minutes before surgery and then three times daily for five days after extraction. The dexamethasone injection focuses the drug near the affected area with minimal systemic absorption, while the oral enzyme therapy aims to break down inflammatory peptides. Participants will be monitored for three months to compare how well each treatment reduces postoperative symptoms. Researchers will assess clinical signs of inflammation, including pain, swelling, and trismus. The study includes regular evaluations to track healing and any side effects. The trial uses a randomized design with single masking to ensure objective comparison of the two treatments.

Age: 18Years +All GendersPhase Not Applicable
1 location
S

Actively Recruiting

Researchers are investigating how living at different altitudes affects the risk and severity of post-dural puncture headache PDPH after spinal anesthesia for cesarean delivery. This prospective cohort study compares women giving birth at a high altitude site in Jumla, Nepal about 2514 meters above sea level, with those at a low altitude site in Dharan, Nepal 350 meters above sea level. The study aims to determine if women native to high altitudes have a higher chance of developing PDPH than those from low altitudes. The study includes women who are scheduled for elective or non-elective cesarean delivery using spinal anesthesia with a 25-gauge pencil point needle. Participants will be grouped based on their native altitude residence one group from high altitude and another from low altitude. Baseline patient information, including anxiety levels, antenatal depression, and any chronic pain or existing headaches, will be recorded. The diagnosis of PDPH will follow international criteria, and spinal anesthesia will be administered at specific lumbar levels in the sitting position. Participants will be closely observed for up to seven days after spinal anesthesia to record the occurrence and severity of PDPH and other headaches. Treatment received for PDPH will be tracked for one month following diagnosis. The study involves initial screening, anesthesia administration during cesarean delivery, and follow-up assessments to monitor headache outcomes and any complications. This helps researchers understand how altitude influences PDPH risk and guides care for women undergoing cesarean delivery with spinal anesthesia.

Age: 18Years +FEMALE
2 locations
E

Actively Recruiting

This research aims to evaluate the use of a lower INR target range 1.5 to 2.5 in patients who have a mechanical bileaflet heart valve implanted in the aortic position. The goal is to determine whether lowering the INR target can reduce bleeding risks without increasing the chance of blood clots or stroke. This study is important for patients who require lifelong warfarin treatment to prevent clot formation on their mechanical heart valves. Participants will be randomly assigned to one of two groups one group will have their warfarin dosing adjusted to maintain an INR target between 1.5 and 2.5, while the other group will follow the standard INR target range as currently recommended. Warfarin therapy is the main intervention, and the study compares these two INR target ranges to assess outcomes related to clotting and bleeding. Treatment and follow-up are expected to last about 2 to 3 years. Throughout the study, participants will be monitored for occurrences of thrombosis, thromboembolism, major and minor bleeding, strokes, heart attacks, and other complications. Researchers will track time spent in the therapeutic INR range and the incidence of extreme INR values. Safety and effectiveness assessments will continue through the study completion, which is anticipated to be approximately 2 to 3 years after enrollment.

Age: 18Years +All GendersPhase 3
45 locations